Status:

RECRUITING

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

Lead Sponsor:

Brown University

Conditions:

Alcohol Use Disorder (AUD)

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target ...

Detailed Description

16 week, between-subject, double-blind, randomized clinical trial (RCT) with doxazosin (16 mg, or maximum tolerated dose, MTD) compared to placebo in 184 treatment seeking individuals with AUD

Eligibility Criteria

Inclusion

  • Male or female, 18 years of age
  • Meet the DSM-5 criteria for AUD
  • Desire to reduce or quit alcohol drinking
  • Breath alcohol (BrAC) = 0.00 at each visit
  • In good health as confirmed by medical history, physical examination and lab tests
  • Willing to adhere to the study procedures
  • Understand informed consent and questionnaires in English at an 8th grade level

Exclusion

  • Women who are breastfeeding or /positive urine test for pregnancy
  • CrCl\<60mL/min
  • Suicide attempt in the last three months
  • Current diagnosis of other substance disorder other than nicotine as assessed by self-report and urine toxicology screen at baseline
  • Current use of medication that may interact with doxazosin and/or yohimbine
  • History of allergy to any alpha receptor blockers
  • Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) score ≥ 8
  • Treatment with disulfiram, naltrexone, acamprosate, topiramate within 1 month prior to screening
  • Treatment with any alpha-blocker
  • Individuals with cardiac heat failure (CHF), as assessed by the medical history, the physical exam and the ECG.
  • Baseline hypotension defined as BP reading lower than 90/60 mmHg
  • Use of phosphodiesterase inhibitors (PDE5) erectile dysfunction medication

Key Trial Info

Start Date :

December 19 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 20 2025

Estimated Enrollment :

184 Patients enrolled

Trial Details

Trial ID

NCT04135846

Start Date

December 19 2019

End Date

December 20 2025

Last Update

September 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Brown University

Providence, Rhode Island, United States, 20923